Latest Information Update: 03 Jul 2002
At a glance
- Originator Aventis; Venezuelan Institute for Scientific Research
- Developer Venezuelan Institute for Scientific Research
- Class Anticoagulants
- Mechanism of Action Factor IXa inhibitors; Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis